What does CUSIP 09058V103 represent in this 13F holders report?

CUSIP 09058V103 is the security identifier for BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock used to aggregate holder disclosures.

How many institutions held BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock in Q4 2013?

76 institutional investors reported BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock for Q4 2013. Use the holders table for investor-level position and value details.

BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)

CUSIP: 09058V103

Q4 2013 13F Holders as of 31 Dec 2013

Type / Class: Equity / Common Stock
Shares outstanding: 210,587,372
Total 13F shares: 34,819,131
Share change: +98,070
Total reported value: $264,754,100
Put/Call ratio: 54%
Price per share: $7.60
Number of holders: 76
Value change: +$745,210
Number of buys: 4
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 09058V103?
CUSIP 09058V103 identifies BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2014
Previous quarter: Q3 2013

Recent filing periods for CUSIP 09058V103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PDT Partners, LLC	13F	Company	0.02%	34,057	$248,000	—	30 Sep 2013	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.02%	33,902	$247,000	—	30 Sep 2013	13F
Joel Isaacson & Co., LLC	13F	Company	0.01%	12,000	$87,000	—	30 Sep 2013	13F
Dynamic Technology Lab Private Ltd	13F	Company	0.01%	10,720	$78,000	—	30 Sep 2013	13F

Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) as of Q4 2013

As of 31 Dec 2013, BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) was held by 76 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,819,131 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, WELLINGTON MANAGEMENT CO LLP, RA CAPITAL MANAGEMENT, LLC, FMR LLC, D. E. Shaw & Co., Inc., VHCP Management, LLC, VANGUARD GROUP INC, TPG Group Holdings (SBS) Advisors, Inc., BlackRock Institutional Trust Company, N.A., and DEERFIELD MANAGEMENT CO. This page lists 76 institutional shareholders reporting positions in this security for the Q4 2013 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2013 vs Q3 2013 Across Filers

Q3 2013 holders

Q4 2013 holders

Holder diff

Investor	Q3 2013 Shares	Q4 2013 Shares	Share Diff	Share Chg %	Q3 2013 Value $	Q4 2013 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.